Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.
NCT04320277
·
clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
UNKNOWN
Status
200
Enrollment
OTHER
Sponsor class
Conditions
Pharmacological Action
Interventions
DRUG:
Baricitinib
Sponsor
Hospital of Prato